Healthcare M&A's new dawn
FTSE 100 drug maker Shire's (SHP) attempt at buying US rare disease specialist Baxalta (BXLT:NYSE) is the latest example of how large cap pharmaceutical M&A strategy is changing.Companies are shunning big mergers that come with a...
13 August 2015